Figure 1
PBN treatment curbs EAE symptoms. (A) Clinical score monitored during EAE (induction at day 0). Treatment with PBN [green; n = 9] or solvent [blue; n = 11] commenced when the individual score reached 2 (between days 12 and 16 after induction, gray zone). Animals of the EAE group [red; n = 6] were left untreated. Shown are means + /− standard error of the mean. For analysis of PBN effects on individual experimental days, ANOVA analysis followed by Tukey’s post-hoc test was performed. p < 0.05 was considered significantly different, illustrated by ≈ PBN versus EAE, # PBN versus solvent, and * PBN versus EAE and solvent. (B) Illustration of scores on day 28 (gray bar in A), showing the mean plus standard error of the mean. *p < 0.05. (C) Clinical symptoms of PBN- [green; n = 9] and solvent- [blue; n = 11] treated animals as well as untreated EAE animals [red; n = 6] (days of treatment). Scores were monitored after the individual onset of treatment (defined as day 0 of treatment). Shown are means + /− standard error of the mean. p < 0.05 was considered significantly different, illustrated by ≈ PBN versus EAE, # PBN versus solvent, and * PBN versus EAE and solvent. (D) Survival of EAE [red] and solvent [blue] animals was significantly lower than that of PBN [green] animals. (D–G) For illustration of the development of clinical symptoms in the experimental groups EAE, solvent, and PBN, the median of scores [1. quartile; 3. quartile] is demonstrated at the starting point of treatment, i.e. day 0 (E), at day 7 of treatment (F) and at the final point of the experiment, i.e. day 20 (G). *p < 0.05.
